CULLINAN THERAPEUTICS

Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023

26 Apr 2023 07:08:32 By Nasdaq GlobeNewswire

Cullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology Days

20 Apr 2023 04:00:00 By Nasdaq GlobeNewswire

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines

27 Mar 2023 04:00:06 By Nasdaq GlobeNewswire

Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting

14 Mar 2023 13:35:18 By Nasdaq GlobeNewswire

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

09 Mar 2023 04:00:01 By Nasdaq GlobeNewswire

Cullinan Oncology to Participate in Cowen’s 43rd Annual Health Care Conference

27 Feb 2023 05:00:02 By Nasdaq GlobeNewswire

Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed

13 Feb 2023 16:00:00 By Nasdaq GlobeNewswire

Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference

02 Feb 2023 13:01:00 By Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Feb 2023 13:41:55 By Nasdaq GlobeNewswire

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

24 Jan 2023 05:00:02 By Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Jan 2023 14:13:42 By Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Dec 2022 14:00:00 By Nasdaq GlobeNewswire

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results

14 Nov 2022 04:00:03 By Nasdaq GlobeNewswire

Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors

02 Nov 2022 05:00:01 By Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Nov 2022 14:23:46 By Nasdaq GlobeNewswire

Cullinan Oncology to Participate in Upcoming Investor Conferences

01 Nov 2022 04:00:01 By Nasdaq GlobeNewswire

Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619

25 Oct 2022 04:00:01 By Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Oct 2022 13:50:00 By Nasdaq GlobeNewswire

Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and the Morgan Stanley Healthcare Conference

07 Sep 2022 05:00:02 By Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Sep 2022 14:27:22 By Nasdaq GlobeNewswire